This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Couch, M. E. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Couch, M. E. Articles by Sidransky, D.

Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer

Authors' Affiliations: ¹ Department of Otolaryngology–Head and Neck Surgery, University of North Carolina, G0412 Neurosciences Hospital, Chapel Hill, North Carolina; ² Departments of Otolaryngology and of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania; ³ Department of Otolaryngology–Head and Neck Surgery, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas; ⁴ Department of Otolaryngology–Head and Neck Surgery and ⁵ Department of Oncology, Medicine, and Molecular Biology and Genetics, Johns Hopkins Hospital, Baltimore, Maryland; ⁶ Virginia Mason Research Center and the University of Washington, Benaroya Research Institute, Seattle, Washington; and ⁷ Roche Molecular Systems, Department of Human Genetics, Alameda, California

Requests for reprints: Robert L. Ferris, Departments of Otolaryngology and Immunology, 5117 Center Avenue, Room 2.26b, Pittsburgh, PA 15213. Phone: 412-623-7738; Fax: 412-623-7768; E-mail: ferrisrl{at}upmc.edu or David Sidransky, Department of Otolaryngology–Head and Neck Surgery, 6252 JHOC, Baltimore, MD 21287. E-mail: dsidrans{at}jhmi.edu.

Purpose: To determine if serologic recognition of p53 mutations at the protein level depends upon the ability of mutant p53 to express new peptide epitopes that bind to human leukocyte antigen (HLA) class II molecules, we used anti-p53 antibody production as a marker for HLA class II–restricted T-cell involvement in head and neck cancer.

Experimental Design: An anti-p53 antibody response was correlated with specific p53 mutations and the patients' HLA class II alleles and haplotypes. HLA binding studies and in vitro stimulation (IVS) of peripheral blood mononuclear cells were done using a mutant versus wild-type HLA-DQ7-binding p53 peptide.

Results: Certain HLA-DQ and HLA-DR alleles were frequently present in p53 seropositive patients who produced serum anti-p53 antibodies. Selected mutated p53 peptides fit published allele-specific HLA class II binding motifs for the HLA-DQ7 or HLA-DR1 molecules. Moreover, a mutant p53 peptide bound with a 10-fold greater affinity than the wild-type p53 peptide to HLA-DQ7 molecules. IVS of CD4⁺ T cells from seven healthy HLA-DQ7⁺ donors using this mutant p53 peptide (p53_220C) was associated with a partial T helper type 2 phenotype compared with IVS using the wild-type p53_210-223 peptide.

Conclusions: Our results support the hypothesis that mutated p53 neoantigens can bind to specific HLA class II molecules, leading to a break in tolerance. This may lead to skewing of the CD4⁺ T lymphocyte response toward a tumor-permissive T helper type 2 profile in head and neck cancer patients, as manifested by seropositivity for p53.